| Autor: |
Safa Belghali, Wafa Hamdi, Kaouther Maatallah, Mohamed Montacer Kchir, L. Abdelmoula, Rawdha Tekaya, A Ben Ouhiba, I. Mahmoud |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Poster Presentations. |
| DOI: |
10.1136/annrheumdis-2017-eular.6177 |
| Popis: |
Background The hip disease is a serious complication of spondyloarthritis (SpA), engaging the functional prognosis of patients. TNF alpha inhibitors are a breakthrough for the treatment of SpA and the management of this complication. Objectives To assess the efficacy of TNF alpha inhibitors on hip involvement in SpA by evaluating the use of intra-articular corticosteroid infiltrations. Methods Observational cohort study that included 94 SpA patients with hip disease (ASAS2009). Two groups were studied. Group 1 (G1): patients under anti-TNF alpha therapy and Group 2 (G2): TNF alpha inhibitors naive patients. Clinical (BASDAI, BASFI, hip (pain/mobility), index of severity for osteoarthritis for the hip (ISH)), biological (CRP) data were assessed and the use of corticosteroid hip joint infiltration was compared. Evaluations were performed and compared between the 2 groups at baseline (T0), two years (T2) and Tn (greater than or equal to 3 years). The correlation study was made by Pearson test. A correlation was considered statistically significant if p Results Group 1 and 2 included 48 and 46 patients respectively. The socio demographic and clinical characteristics of the disease were comparable between the two groups. Biological and radiological assessments of the two groups were comparable at T0. Group 1 had however a more active disease and a greater functional impairment. NSAIDs were prescribed in 40% of patients in G1 and 86% in G2 (p Conclusions Hip involvement is a marker of severity of spondyloarthritis. Anti-TNF alpha treatment is effective on hip disease. It reduces the use of intra articular injections of corticosteroids. Disclosure of Interest None declared |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
